Tumor-Associated Macrophages (TAMs) in Cancer: Understanding Their Role in Tumor Progression and New Therapeutic Strategies

 

Tumor-Associated Macrophages in Cancer: New Strategies for Cancer Therapy

Introduction

Cancer is not driven by malignant cells alone. Tumors develop within a complex biological environment containing immune cells, stromal cells, blood vessels, extracellular matrix components, signaling molecules, and metabolic factors. This environment, known as the tumor microenvironment (TME), can influence tumor growth, invasion, metastasis, immune escape, and response to treatment.

Among the immune cells present within tumors, tumor-associated macrophages (TAMs) have emerged as important regulators of cancer biology. TAMs are macrophages located within or around tumor tissues and can acquire different functional states in response to signals from cancer cells and the surrounding microenvironment. Research has shown that TAMs can participate in tumor progression, angiogenesis, immune suppression, metastasis, and treatment resistance, while macrophages can also contribute to antitumor immune responses under particular conditions.

This functional flexibility has made TAMs an important area of cancer research. Instead of viewing macrophages simply as either beneficial or harmful immune cells, current research increasingly focuses on their heterogeneity, plasticity, spatial distribution, and interactions with other cells.

Understanding how TAMs influence cancer may open opportunities for developing new therapeutic strategies, including macrophage depletion, inhibition of macrophage recruitment, functional reprogramming, and combination approaches with immunotherapy.

 

What Are Tumor-Associated Macrophages?

Macrophages are immune cells involved in tissue maintenance, inflammation, pathogen defense, tissue repair, and clearance of damaged cells. In tumors, macrophages can be recruited from circulating monocytes or arise from tissue-resident macrophage populations.

Once they enter the tumor microenvironment, macrophages are exposed to a variety of signals produced by cancer cells, stromal cells, cytokines, chemokines, metabolites, and dying cells.

These signals can alter macrophage behavior and gene expression.

The resulting tumor-associated macrophages can perform multiple functions, including:

• Supporting or suppressing inflammation
• Regulating tumor-cell growth
• Influencing blood-vessel formation
• Remodeling the extracellular matrix
• Modulating T-cell activity
• Supporting cancer-cell invasion and metastasis
• Influencing responses to chemotherapy and immunotherapy

Importantly, TAMs are not a single uniform population. Their functional states can vary between cancer types, patients, tumor regions, and stages of disease. Recent research therefore emphasizes TAM heterogeneity rather than treating all TAMs as one biological category.

 

Understanding the M1–M2 Macrophage Framework

A commonly used framework divides macrophages into broadly M1-like and M2-like functional states.

M1-like macrophages are generally associated with inflammatory and antitumor activities. They can produce inflammatory mediators and participate in immune responses against abnormal cells.

M2-like macrophages are traditionally associated with anti-inflammatory and tissue-repair functions. Within tumors, M2-like programs have frequently been linked to immunosuppression, angiogenesis, tissue remodeling, and tumor progression.

However, the M1/M2 classification is a simplified model.

Tumor-associated macrophages can exist across a broad spectrum of functional states rather than belonging to two completely separate categories. Their behavior can change in response to environmental signals, treatment, oxygen availability, metabolic conditions, and interactions with neighboring cells.

Therefore, modern TAM research is increasingly investigating macrophage states, cellular programs, lineage, spatial location, and functional plasticity.

 

How Are TAMs Recruited Into Tumors?

Cancer cells and other components of the tumor microenvironment can release signaling molecules that attract macrophages and their precursors.

Chemokine signaling is particularly important in macrophage recruitment. For example, the CCL2–CCR2 axis can contribute to the recruitment of monocytes toward tumor tissues.

The CSF-1/CSF-1R signaling pathway is another important pathway involved in macrophage survival, differentiation, recruitment, and function. Because of its role in TAM biology, CSF-1R has become an important target for therapeutic research.

Once recruited, these cells can be exposed to tumor-derived signals that reshape their phenotype and function.

This creates a dynamic process:

Tumor signals → macrophage recruitment → macrophage functional adaptation → TME remodeling → changes in tumor progression and treatment response

Understanding this process may help researchers identify new intervention points.

 

TAMs and Tumor Growth

TAMs can influence cancer-cell proliferation through interactions with malignant cells and other components of the tumor microenvironment.

Some TAM populations release growth-promoting factors, cytokines, and signaling molecules that can support tumor-cell survival and proliferation.

They can also modify the surrounding extracellular matrix, creating conditions that facilitate tumor-cell movement and invasion.

The biological importance of TAMs can vary depending on tumor type and microenvironment. Consequently, researchers are studying not only the quantity of TAMs but also their functional characteristics and spatial distribution.

 

TAMs and Tumor Angiogenesis

Tumors require access to nutrients and oxygen as they grow. Angiogenesis—the formation of new blood vessels—is therefore an important component of tumor progression.

TAMs can contribute to angiogenic processes by producing signaling molecules that influence endothelial cells and vascular development.

Some TAM populations are particularly enriched in hypoxic or vascular regions of tumors. Research has linked TAM-associated signaling with the production of angiogenic factors, extracellular-matrix remodeling, and changes in tumor vasculature.

This relationship makes TAMs relevant to research investigating how tumors establish and maintain abnormal vascular networks.

 

TAMs and Cancer Metastasis

Metastasis occurs when cancer cells spread from the original tumor to distant organs.

TAMs can influence several stages associated with metastatic progression, including:

• Extracellular-matrix remodeling
• Cancer-cell invasion
• Tumor-cell migration
• Blood-vessel interactions
• Immune suppression
• Establishment of supportive metastatic environments

Macrophage-derived factors can modify the tissue surrounding cancer cells and may help create conditions that support tumor dissemination.

Research into TAMs is therefore increasingly connected with studies of tumor invasion, metastatic niches, and cancer recurrence.

 

TAMs and Immune Suppression

One of the most important areas of TAM research is their interaction with the immune system.

Effective anticancer immunity requires immune cells such as cytotoxic T cells and natural killer cells to recognize and eliminate malignant cells.

However, tumors can develop immunosuppressive environments that interfere with these responses.

Certain TAM populations can contribute to this environment through:

• Immunosuppressive cytokine production
• Altered antigen presentation
• T-cell inhibition
• Regulation of regulatory T cells
• Suppression of natural killer-cell activity
• Expression of immune-regulatory molecules

These interactions can reduce the effectiveness of antitumor immune responses.

As a result, TAMs are increasingly being studied as potential components of immune-resistant tumor microenvironments.

 

TAMs and Cancer Treatment Resistance

Another important research area is the relationship between TAMs and treatment resistance.

Cancer treatment can alter the tumor microenvironment. Chemotherapy, radiotherapy, and immunotherapy may cause cellular stress, tissue damage, inflammatory responses, and changes in immune-cell composition.

TAMs can participate in tissue-repair and inflammatory processes following treatment. Depending on the context, these responses may influence treatment effectiveness.

TAM-associated mechanisms have also been investigated in resistance to immune-checkpoint blockade.

This has led researchers to investigate whether modifying TAM activity could make tumors more responsive to existing therapies.

 

Therapeutic Strategies Targeting TAMs

The growing understanding of TAM biology has led to several therapeutic approaches.

1. Blocking TAM Recruitment

One strategy is to prevent excessive recruitment of macrophages into tumor tissues.

Researchers are investigating pathways such as:

• CCL2–CCR2
• CSF-1–CSF-1R
• Other chemokine and cytokine signaling pathways

The goal is to reduce the accumulation of tumor-supportive macrophage populations.

However, because macrophages also have important physiological functions, selective targeting remains an important challenge.

 

2. TAM Depletion

Another approach is to reduce the number of macrophages that support tumor progression.

Therapeutic research has investigated pathways involved in macrophage survival and maintenance, including CSF-1R signaling.

Some macrophage-targeting approaches have demonstrated antitumor activity in preclinical models, while clinical development continues to explore how these strategies can be applied safely and effectively.

 

3. Reprogramming TAMs

Instead of eliminating macrophages, researchers are exploring whether TAMs can be re-educated toward more antitumor functions.

This strategy is based on the plasticity of macrophages.

Rather than simply removing TAMs, therapeutic interventions may attempt to modify their functional state and restore immune-stimulatory activity.

Research has explored cytokine signaling, innate immune pathways, nanoparticles, and other approaches for TAM reprogramming.

This concept is particularly interesting because macrophages can potentially become active participants in antitumor immunity.

 

4. Enhancing Macrophage-Mediated Phagocytosis

Macrophages naturally possess the ability to engulf and eliminate abnormal cells.

Some tumors exploit inhibitory signals that prevent macrophages from efficiently recognizing and engulfing cancer cells.

One extensively studied pathway is the CD47–SIRPα signaling axis, often described in cancer research as a "don't-eat-me" signal.

Blocking this type of inhibitory signaling may increase macrophage-mediated phagocytosis in selected experimental settings.

This has created interest in macrophage-centered immunotherapy strategies designed to enhance the immune system's ability to recognize malignant cells.

 

TAMs and Combination Immunotherapy

TAM-targeted therapy is increasingly being investigated in combination with other cancer treatments.

Potential combinations include:

TAM targeting + immune checkpoint inhibitors

The objective is to modify an immunosuppressive tumor environment and potentially improve immune-cell activity.

TAM targeting + chemotherapy

Chemotherapy can alter the tumor microenvironment, and macrophage modulation may influence how tumors respond to treatment.

TAM targeting + radiotherapy

Radiotherapy can cause changes in immune-cell populations and inflammatory signaling. TAM-directed approaches are therefore being studied as potential partners for radiation-based treatment.

TAM targeting + targeted therapies

Molecularly targeted treatments may be combined with macrophage-modulating approaches to address multiple components of tumor biology.

The underlying concept is that targeting cancer cells alone may not be sufficient in some tumors; modifying the surrounding immune ecosystem could provide an additional therapeutic strategy.

 

The Importance of TAM Heterogeneity

One of the biggest challenges in TAM research is heterogeneity.

Two tumors may contain similar numbers of macrophages but very different macrophage populations.

Even within a single tumor, macrophages located near:

• Blood vessels
• Hypoxic regions
• Invasive tumor margins
• Necrotic areas
• Stromal compartments

may exhibit different molecular and functional characteristics.

Recent research therefore emphasizes spatial biology and single-cell approaches for understanding TAM populations.

This shift could improve the ability to identify which macrophage populations are relevant for particular therapeutic strategies.

 

Biomarkers for Studying TAMs

Researchers use several markers to characterize macrophage populations.

Commonly studied markers include:

• CD68
• CD163
• CD206
• CSF-1R
• Other macrophage-associated molecular markers

However, no single marker completely captures the functional complexity of TAMs.

Combining multiple markers with transcriptomic, proteomic, imaging, and spatial information may provide a more comprehensive understanding of TAM biology.

This is particularly relevant for precision oncology, where researchers seek to identify biological characteristics that can help guide treatment strategies.

 

Spatial Biology and TAM Research

The location of a macrophage within a tumor can be as important as its molecular phenotype.

For example, macrophages positioned near blood vessels may perform different functions from those located within hypoxic tumor regions.

Modern technologies such as:

• Multiplex immunohistochemistry
• Multiplex immunofluorescence
• Spatial transcriptomics
• Imaging mass cytometry
• Single-cell RNA sequencing
• Digital pathology

are helping researchers investigate these differences.

Combining spatial information with molecular data may reveal how TAMs interact with cancer cells, T cells, fibroblasts, endothelial cells, and other components of the tumor microenvironment.

 

Artificial Intelligence in TAM Research

Artificial intelligence and computational pathology may also contribute to TAM research.

AI-assisted image analysis can help researchers quantify immune-cell populations and analyze their spatial relationships within tissue samples.

Potential applications include:

• Automated macrophage detection
• Spatial distribution analysis
• Digital pathology
• Image-based biomarker discovery
• Prediction of immune-cell interactions
• Integration of histology with molecular data

When combined with genomic and transcriptomic information, computational approaches may help researchers develop more detailed models of the tumor microenvironment.

 

TAMs and Precision Oncology

Precision oncology traditionally focuses on molecular characteristics of cancer cells, such as mutations, gene-expression patterns, and biomarkers.

However, the tumor microenvironment is increasingly recognized as another layer of biological information.

TAM profiling could potentially contribute to precision oncology by helping researchers understand:

• Which tumors contain immunosuppressive macrophage populations
• Which patients may have macrophage-driven immune resistance
• Which therapeutic pathways could be targeted
• How the immune microenvironment changes during treatment
• Which combination therapies may be biologically appropriate

This approach moves toward a broader concept of precision cancer treatment that considers both tumor-cell biology and immune-microenvironment biology.

 

Challenges in TAM-Targeted Therapy

Despite promising research, several challenges remain.

TAM heterogeneity

TAMs differ between patients, cancer types, and tumor regions, making universal treatment strategies difficult.

Macrophage plasticity

Macrophages can change their functional states in response to environmental signals. Eliminating one population may not permanently modify the tumor microenvironment.

Systemic effects

Macrophages perform essential functions throughout the body. Therapies targeting macrophage pathways therefore need appropriate specificity.

Biomarker limitations

Researchers still need robust biomarkers to determine which patients are most likely to benefit from specific TAM-targeted approaches.

Tumor-specific biology

A strategy that works in one cancer type may not produce the same biological effects in another.

Combination-treatment complexity

TAM-targeted therapies may need to be combined with chemotherapy, radiotherapy, targeted therapy, or immunotherapy, making treatment design more complex.

These challenges explain why TAM research continues to focus heavily on biological characterization and patient selection.

 

The Future of TAM-Directed Cancer Therapy

Future TAM research is likely to move beyond simple M1-versus-M2 classification.

Researchers are increasingly investigating macrophage states at single-cell and spatial levels.

Future studies may combine:

Single-cell profiling + spatial biology + digital pathology + proteomics + genomics + clinical data

to create detailed maps of macrophage populations within tumors.

Another important direction is biomarker-guided TAM therapy, in which treatment strategies are selected according to the specific macrophage programs present in an individual patient's tumor.

Engineered macrophage therapies are also attracting research interest. Approaches such as CAR macrophages (CAR-M) seek to modify macrophages so they can recognize specific tumor-associated targets and participate more effectively in antitumor activity.

The combination of macrophage engineering with other immunotherapies could represent another area of investigation in next-generation cancer treatment.

 

Conclusion

Tumor-associated macrophages are an important component of the cancer microenvironment and can influence tumor progression, angiogenesis, metastasis, immune regulation, and treatment response.

Their biological complexity means that TAMs cannot simply be classified as uniformly beneficial or harmful. Instead, their functions depend on cellular state, tumor type, spatial location, signaling environment, and interactions with other cells.

Current research is exploring several approaches to target TAMs, including blocking recruitment, reducing tumor-supportive macrophage populations, reprogramming macrophage function, enhancing phagocytosis, and combining TAM-directed therapies with immunotherapy.

As single-cell technologies, spatial biology, digital pathology, artificial intelligence, and multi-omics approaches continue to advance, researchers may gain a more precise understanding of macrophage behavior within individual tumors.

The future of TAM research may therefore contribute to a broader model of precision oncology—one that considers not only the genetic characteristics of cancer cells but also the immune ecosystem surrounding them.

 

Join Oncology Summit-2027

The International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027) brings together researchers, clinicians, oncologists, scientists, healthcare professionals, academics, and industry experts to exchange knowledge on emerging developments in oncology and cancer care.

Researchers working on tumor-associated macrophages, cancer immunology, tumor microenvironment, macrophage biology, immunotherapy, precision oncology, cancer biomarkers, translational oncology, and related fields are invited to share their latest research and perspectives.

International Experts Summit on Oncology & Cancer Care

March 25–27, 2027
Osaka, Japan

Researchers and healthcare professionals are encouraged to submit their abstracts and participate in scientific discussions focused on emerging advances in cancer research and treatment.

 

Frequently Asked Questions (FAQs)

1. What are tumor-associated macrophages?

Tumor-associated macrophages (TAMs) are macrophages found within or around tumor tissues. They can acquire different functional states in response to signals from cancer cells and the tumor microenvironment.

2. What is the role of TAMs in cancer?

TAMs can influence tumor growth, angiogenesis, metastasis, immune regulation, extracellular-matrix remodeling, and treatment response. Their effects can vary depending on their functional state and tumor environment.

3. What is the difference between M1 and M2 macrophages?

M1-like macrophages are generally associated with inflammatory and antitumor functions, while M2-like macrophages are traditionally associated with anti-inflammatory and tissue-repair functions and can support tumor progression in some contexts. Modern research recognizes that TAM states exist along a broader continuum.

4. Can TAMs suppress the immune response?

Yes. Certain TAM populations can contribute to an immunosuppressive tumor microenvironment by affecting T cells, natural killer cells, regulatory T cells, cytokine signaling, and other immune pathways.

5. How can TAMs be targeted in cancer?

Research strategies include blocking macrophage recruitment, targeting macrophage survival pathways, depleting selected TAM populations, reprogramming TAMs toward antitumor functions, and enhancing macrophage-mediated phagocytosis.

6. What is the CSF-1/CSF-1R pathway?

CSF-1/CSF-1R signaling is involved in macrophage development, survival, recruitment, and function. Because of its importance in macrophage biology, CSF-1R has been investigated as a therapeutic target in cancer research.

7. Can TAM-targeted therapy be combined with immunotherapy?

Researchers are investigating combinations of TAM-targeted strategies with immune checkpoint inhibitors and other immunotherapies. The goal is to modify immunosuppressive components of the tumor microenvironment and potentially improve antitumor immune responses.

8. What biomarkers are used to study TAMs?

Researchers commonly investigate macrophage-associated markers such as CD68, CD163, CD206, and CSF-1R. However, individual markers do not fully describe TAM heterogeneity, so multiple molecular and spatial measurements may be needed.

9. How is AI being used in TAM research?

AI and computational pathology can assist with detecting macrophages in tissue images, measuring their spatial distribution, analyzing cellular interactions, and integrating imaging with molecular information.

10. What is the future of TAM research?

Future research is expected to focus increasingly on TAM heterogeneity, spatial biology, single-cell analysis, macrophage reprogramming, engineered macrophage therapies, biomarker-guided treatment, and rational combinations with other cancer therapies.